Susan R Davis1, Mary Panjari, Frank Z Stanczyk. 1. Women's Health Research Program, Department of Epidemiology and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, Victoria 3004, Australia. susan.davis@monash.edu
Abstract
CONTEXT: It has been proposed that because dehydroepiandrosterone (DHEA) and its sulfate, DHEAS, are important precursors for estrogen and androgen production, treatment with DHEA is a physiologically based strategy for the alleviation of hormone deficiency symptoms in postmenopausal women. We have summarized the physiology of DHEA in women and reviewed the findings from randomized controlled trials (RCT) of the effects of DHEA therapy in postmenopausal women with normal adrenal function. EVIDENCE ACQUISITION: We reviewed the medical literature for key papers investigating DHEA physiology and RCT of the use of DHEA in postmenopausal women through November 2010. The focus was on sexual function, well-being, metabolic parameters, and cognition as study endpoints. EVIDENCE SYNTHESIS: Although cross-sectional studies have indicated a link between low DHEA levels and impaired sexual function, well-being, and cognitive performance in postmenopausal women, placebo-controlled RCT do not show benefits of oral DHEA for any of these outcomes or favorable effects on lipids and carbohydrate metabolism. CONCLUSIONS: Taken together, findings from this review of the published literature of studies do not support the use of DHEA in postmenopausal women at this time.
CONTEXT: It has been proposed that because dehydroepiandrosterone (DHEA) and its sulfate, DHEAS, are important precursors for estrogen and androgen production, treatment with DHEA is a physiologically based strategy for the alleviation of hormone deficiency symptoms in postmenopausal women. We have summarized the physiology of DHEA in women and reviewed the findings from randomized controlled trials (RCT) of the effects of DHEA therapy in postmenopausal women with normal adrenal function. EVIDENCE ACQUISITION: We reviewed the medical literature for key papers investigating DHEA physiology and RCT of the use of DHEA in postmenopausal women through November 2010. The focus was on sexual function, well-being, metabolic parameters, and cognition as study endpoints. EVIDENCE SYNTHESIS: Although cross-sectional studies have indicated a link between low DHEA levels and impaired sexual function, well-being, and cognitive performance in postmenopausal women, placebo-controlled RCT do not show benefits of oral DHEA for any of these outcomes or favorable effects on lipids and carbohydrate metabolism. CONCLUSIONS: Taken together, findings from this review of the published literature of studies do not support the use of DHEA in postmenopausal women at this time.
Authors: Krzysztof Rutkowski; Paweł Sowa; Joanna Rutkowska-Talipska; Anna Kuryliszyn-Moskal; Ryszard Rutkowski Journal: Drugs Date: 2014-07 Impact factor: 9.546
Authors: Alan J Conley; Frank Z Stanczyk; John H Morrison; Pawel Borowicz; Kurt Benirschke; Nancy A Gee; Bill L Lasley Journal: Menopause Date: 2013-03 Impact factor: 2.953
Authors: Fatemah A Alherz; Amal A El Daibani; Maryam S Abunnaja; Ahsan F Bairam; Mohammed I Rasool; Yoichi Sakakibara; Masahito Suiko; Katsuhisa Kurogi; Ming-Cheh Liu Journal: Mol Cell Endocrinol Date: 2019-08-07 Impact factor: 4.102
Authors: Rivka Ben Dor; Christine E Marx; Lawrence J Shampine; David R Rubinow; Peter J Schmidt Journal: Psychopharmacology (Berl) Date: 2015-06-25 Impact factor: 4.530
Authors: Queenie Ho Yan Wong; Tracy Wing Yee Yeung; Sofie Shuk Fei Yung; Jennifer Ka Yee Ko; Hang Wun Raymond Li; Ernest Hung Yu Ng Journal: J Assist Reprod Genet Date: 2018-03-09 Impact factor: 3.412